Closure of macular hole secondary to ischemic hemi-central retinal vein occlusion by retinal photocoagulation and topical anti-inflammatory treatment

Asato, Teru; Nagai, Norihiro; Suzuki, Misa; Uchida, Atsuro; Kurihara, Toshihide; Ban, Norimitsu; Minami, Sakiko; Shinoda, Hajime; Ozawa, Yoko

doi:10.1007/s10103-020-03133-9

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the retinal vessels are anatomically narrowed, especially at the arteriovenous junction, at the cribriform plate The crowding effect of the layer, and many intravascular lesions that cause thrombosis Inflammatory diseases of trauma may lead to vascular occlusion. [ 14 15 ] Retina VEGF and inflammatory cytokines induced by ischemia increase vascular permeability and leakage. The treatment of ME includes macular laser photocoagulation after an operation, anti-VEGF drugs, pstA and dexamethasone were injected into vitreous vitrectomy.…”

Section: Discussionmentioning

confidence: 99%

“…The pathogenesis is still unclear. However, the retinal vessels are anatomically narrowed, especially at the arteriovenous junction, at the cribriform plate The crowding effect of the layer, and many intravascular lesions that cause thrombosis Inflammatory diseases of trauma may lead to vascular occlusion [14,15] . Retina VEGF and inflammatory cytokines induced by ischemia increase vascular permeability and leakage.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparative efficacy and safety of antivascular endothelial growth factors for central retinal vein occlusion

Liu

Wang

et al. 2021

Medicine

View full text Add to dashboard Cite

Background: Central retinal vein occlusion (CRVO) is one of the most common retinal vascular diseases, which is closely related to systemic diseases like hypertension, diabetes and arteriosclerosis. Due of its blinding, it will seriously reduce the quality of life. Macular edema (ME) caused by CRVO is one of the serious complications of visual impairment. We found that the severity of ME in CRVO was positively associated with vascular endothelial growth factor (VEGF) in the anterior chamber. With the accelerated pace of modern life and the changed dietary structure, the incidence of this disease will continue to rise. Therefore, it is of great practical significance to seek effective treatment methods. Intraocular injection of anti-VEGF can effectively alleviate ME and improve visual acuity, showing excellent clinical application prospects. In recent years, there have been some new understandings and advances on the etiology and treatment methods of the present disease, such as the deepening into the molecular biology and gene level. Clinical studies on the efficacy of the disease have emerging. Therefore, a network meta-analysis (NMA) of anti-VEGF treatment for CRVO is particularly necessary to systematically compare its efficacy. Methods: The two reviewers will comprehensively retrieved electronic databases such as PubMed, The Cochrane Library, Wanfang database, Web of Science, Chinese Scientifific Journals Database, EMBASE, China National Knowledge Infrastructure, and China BioMedical Literature. A randomized controlled trial for CRVO against VEGF between January 2010 and June 2021 was included according to the relevant content of the study. In addition, 2 researchers will screen the literature to assess the risk bias for the included articles. We will evaluate the collected evidence and data using a Bayesian NMA method, and analyzed it with STATA and WinBUGS software. Results: Anti-VEGF is one of the effective methods for ME in CRVO patients, accordingly, this study will evaluate its efficacy and safety using a Bayesian NMA system. Conclusion: This study can provide an effective rationale for the clinical application of anti-VEGF for CRVO, contribute to the treatment of CRVO and patient condition rehabilitation in clinical work. Ethics and dissemination: Do not require. INPLASY registration number: INPLASY2021110073.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Comparative efficacy and safety of antivascular endothelial growth factors for central retinal vein occlusion

Liu

Wang

et al. 2021

Medicine

View full text Add to dashboard Cite

show abstract

“…Proportional mixing evaporation Covalent connection Get rtPA occlusion, the blood vessels of the fundus veins were congested and dilated, and the retina appeared edema and hemorrhage, as well as cotton wool spots, exudation and macular edema. Macular edema is the cause of the sharp decline in vision, and macular edema can occur in 5-15% of BRVO (14)(15). Subretinal vein vascular obstructive macular edema can affect the quality of daily life of macular patients when it is severe.…”

Section: Mixed Reaction Synthetic Copolymer Injectionmentioning

confidence: 99%

Recombinant Plasminogen Activator Modified Nanoparticles for Targeting Thrombolysis in Branch Retinal Vein Occlusion

Zhang¹,

Han²,

Zhang³

et al. 2022

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Branch Retinal Vein Occlusion (BRVO) is the second chronic branch retinal vascular disease that causes abnormal vision loss after acute branch retinal disease in type 2 diabetes. There is no scientific conclusion about its specific pathogenic mechanism at present. Most clinical scholars generally support the theory that the partial human anatomical structure and various systemic risk psychological factors cause insufficient oxygen supply and hemostasis in the local branch retinal arteries. The research results of this article aim to reconstruct a non-nanocell-targeted thrombolytic drug delivery system without modification of rtPA without polyethylene glycol-methyl polycaprolactone and to re-evaluate its thrombus targeting and dissolution. The effect and safety of thrombus provide a new strategy for realizing combined treatment of thrombus. It is a study on the targeting of rtPA-NP to thrombus and its thrombolytic properties. HPLC method was used to detect the binding of fibrin clot prepared in vitro with coumarin-6 labeled NP and rtPA-NP; immunofluorescence technique was used to observe the location of nanomedicine and fibrin clot in branch retinal vein occlusion model Condition. The rtPA-NP drug delivery system constructed in this study not only retains the activity of rtPA and good thrombus targeting but also significantly prolongs its half-life and simplifies the way of administration. The therapeutic efficiency of rtPA-NP thrombus targeted administration on branch retinal vein occlusion reached 85.64%. The successful construction of the rtPA-NP thrombus targeted drug delivery system provides a new way for thrombosis treatment and lays the foundation for the future combination of anticoagulants and vascular protection drugs to achieve the combined treatment of thrombosis and the development of safe and efficient thrombolytic drugs.

show abstract

Scoping review of nonsurgical treatment options for macular holes

Lee,

Bahrami,

Selva

et al. 2024

Survey of Ophthalmology

View full text Add to dashboard Cite

Closure of macular hole secondary to ischemic hemi-central retinal vein occlusion by retinal photocoagulation and topical anti-inflammatory treatment

Cited by 3 publications

References 5 publications

Comparative efficacy and safety of antivascular endothelial growth factors for central retinal vein occlusion

Comparative efficacy and safety of antivascular endothelial growth factors for central retinal vein occlusion

Recombinant Plasminogen Activator Modified Nanoparticles for Targeting Thrombolysis in Branch Retinal Vein Occlusion

Scoping review of nonsurgical treatment options for macular holes

Contact Info

Product

Resources

About